SciSparc | 6-K：海外発行者報告書（決算情報）

SEC11/05 05:04

Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome

Benzinga10/01 08:09

SciSparc Receives FDA Approval To Launch Pivotal Phase IIb Trial For Tourette Syndrome Treatment SCI-110 In U.S., Following Promising Phase IIa Results Showing Up To 40% Tic Reduction

Benzinga09/30 21:27

SciSparc: Amitay Weiss Also Serves as Chairman of Bd of Directors of Purchaser >SPRC

Dow Jones09/26 21:11

SciSparc Will Receive Cash Consideration of $700,000 in Exchange for Shrs That Constitute 27% of MitoCareX Ownership >SPRC

Dow Jones09/26 21:09

SciSparc: Intended Selling Valuation Represents Increase of 47% From Valuation at Time of Initial Investment in MitoCareX Bio >SPRC

Dow Jones09/26 21:06